Skip to main content
Top
Published in: Clinical and Experimental Nephrology 2/2014

01-04-2014 | Original Article

Comparison between consecutive and intermittent steroid pulse therapy combined with tonsillectomy for clinical remission of IgA nephropathy

Authors: Daigo Kamei, Takahito Moriyama, Takashi Takei, Sachiko Wakai, Kosaku Nitta

Published in: Clinical and Experimental Nephrology | Issue 2/2014

Login to get access

Abstract

Background

In recent years, tonsillectomy and steroid pulse (TSP) therapy have been widely performed in Japan. However, there is no consensus about the treatment protocol and indication.

Methods

In this retrospective analysis, we compared patients who received tonsillectomy plus intermittent steroid pulse (SP) therapy three times in 6 months (ISP group, n = 44) with patients who received tonsillectomy plus 3 weeks of consecutive SP therapy (CSP group, n = 46) within 1 year after renal biopsy. These two different protocols were performed at two different institutions. We analyzed the clinical and histological background and clinical remission (CR), defined as disappearance of urine abnormalities at 18 months after starting treatment.

Results

Before treatment, there was no significant difference in the clinical findings except for sex between the two groups. In ISP group and CSP group, mean estimated glomerular filtration rate was 82.1 ± 20.9 and 85.9 ± 19.1 ml/min/1.73 m2, median proteinuria was 0.55 and 0.56 g/day, and median urinary red blood cells were 20 (10–20) and 20 (6–30)/high power filed. The histological (H) grade was lower in the CSP than the ISP group (p = 0.022). The remission rate of proteinuria, hematuria, and rate of CR by the Kaplan–Meier method and logrank test were significantly higher in the CSP group than in the ISP group (CSP vs. ISP group; proteinuria: 97.8 vs. 77.3 %, p < 0.001, hematuria: 97.8 vs. 75.0 %, p = 0.005, CR: 95.6 vs. 63.6 %, p < 0.001). In the Cox proportional hazard model (forced entry), SP protocol and proteinuria before treatment were significantly associated with CR [SP protocol: hazard ratio (HR) 2.50, 95 % confidence interval (CI) 1.46–4.30, p = 0.001, proteinuria: HR 0.81, 95 % CI 0.68–0.96, p = 0.013)]. However H-grade was associated with remission of proteinuria (H-grade: hazard ratio (HR) 0.56, 95 % confidence interval (CI) 0.37–0.85, p = 0.006), and this result meant histological bias affected the remission of proteinuria.

Conclusions

The difference of the protocol of TSP therapy may have some effect on the CR of IgAN, though the histological bias was observed in this study. The appropriate protocol and indication of TSP therapy must be analyzed and determined in the randomized controlled trial.
Literature
1.
go back to reference Berger J, Hinglais N. Inter capillary deposits of IgA-IgG. J Urol Nephrol. 1968;74:694–5. Berger J, Hinglais N. Inter capillary deposits of IgA-IgG. J Urol Nephrol. 1968;74:694–5.
2.
go back to reference D’Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000;36:227–37.PubMedCrossRef D’Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000;36:227–37.PubMedCrossRef
3.
go back to reference Koyama A, Igarashi M, Kobayashi M. Coworkers of the research group on progressive renal disease. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Am J Kidney Dis. 1997;29:526–32.PubMedCrossRef Koyama A, Igarashi M, Kobayashi M. Coworkers of the research group on progressive renal disease. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Am J Kidney Dis. 1997;29:526–32.PubMedCrossRef
4.
go back to reference Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.PubMedCrossRef Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.PubMedCrossRef
5.
go back to reference Miura N, Imai H, Kikuchi S, Hayashi S, Endoh M, Kawamura T, et al. Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clin Exp Nephrol. 2009;13:460–6.PubMedCrossRef Miura N, Imai H, Kikuchi S, Hayashi S, Endoh M, Kawamura T, et al. Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clin Exp Nephrol. 2009;13:460–6.PubMedCrossRef
6.
go back to reference Kawaguchi T, Ieiri N, Yamazaki S, Hayashino Y, Gillespie B, Miyazaki M, et al. Clinical effectiveness of steroid pulse therapy combined with tonsillectomy in patients with immunoglobulin A nephropathy presenting glomerular haematuria and minimal proteinuria. Nephrology. 2010;15:116–23.PubMedCrossRef Kawaguchi T, Ieiri N, Yamazaki S, Hayashino Y, Gillespie B, Miyazaki M, et al. Clinical effectiveness of steroid pulse therapy combined with tonsillectomy in patients with immunoglobulin A nephropathy presenting glomerular haematuria and minimal proteinuria. Nephrology. 2010;15:116–23.PubMedCrossRef
7.
go back to reference Ieiri N, Hotta O, Sato T, Taguma Y. Significance of the duration of nephropathy for achieving clinical remission in patients with IgA nephropathy treated by tonsillectomy and steroid pulse therapy. Clin Exp Nephrol. 2012;16:122–9.PubMedCrossRef Ieiri N, Hotta O, Sato T, Taguma Y. Significance of the duration of nephropathy for achieving clinical remission in patients with IgA nephropathy treated by tonsillectomy and steroid pulse therapy. Clin Exp Nephrol. 2012;16:122–9.PubMedCrossRef
8.
go back to reference Sato M, Hotta O, Tomioka S, Horigome I, Chiba S, Miyazaki M, et al. Cohort study of advanced IgA nephropathy: efficacy and limitations of corticosteroids with tonsillectomy. Nephrol Clin Pract. 2002;93:c137–45.CrossRef Sato M, Hotta O, Tomioka S, Horigome I, Chiba S, Miyazaki M, et al. Cohort study of advanced IgA nephropathy: efficacy and limitations of corticosteroids with tonsillectomy. Nephrol Clin Pract. 2002;93:c137–45.CrossRef
9.
go back to reference Nakagawa N, Kabara M, Matsuki M, Chinda J, Fujino T, Hirayama T, et al. Retrospective comparison of the efficacy of tonsillectomy with and without steroid-pulse therapy in IgA nephropathy patients. Intern Med. 2012;51:1323–8.PubMedCrossRef Nakagawa N, Kabara M, Matsuki M, Chinda J, Fujino T, Hirayama T, et al. Retrospective comparison of the efficacy of tonsillectomy with and without steroid-pulse therapy in IgA nephropathy patients. Intern Med. 2012;51:1323–8.PubMedCrossRef
10.
go back to reference Maeda I, Hayashi T, Kogawa Sato K, Okumoto Shibata M, Hamada M, Kishida M, et al. Tonsillectomy has beneficial effects on remission and progression of IgA nephropathy independent of steroid therapy. Nephrol Dial Transpl. 2012;27:2806–13.CrossRef Maeda I, Hayashi T, Kogawa Sato K, Okumoto Shibata M, Hamada M, Kishida M, et al. Tonsillectomy has beneficial effects on remission and progression of IgA nephropathy independent of steroid therapy. Nephrol Dial Transpl. 2012;27:2806–13.CrossRef
11.
go back to reference Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol. 2008;3:1301–7.PubMedCentralPubMedCrossRef Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol. 2008;3:1301–7.PubMedCentralPubMedCrossRef
12.
go back to reference Ochi A, Moriyama T, Takei T, Uchida K, Nitta K. Comparison between steroid pulse therapy alone and in combination with tonsillectomy for IgA nephropathy. Int Urol Nephrol. 2013;52:193–9. Ochi A, Moriyama T, Takei T, Uchida K, Nitta K. Comparison between steroid pulse therapy alone and in combination with tonsillectomy for IgA nephropathy. Int Urol Nephrol. 2013;52:193–9.
13.
go back to reference Chapter 10: Immunoglobulin A nephropathy. Kidney Int. 2012; supple 2:209–17. Chapter 10: Immunoglobulin A nephropathy. Kidney Int. 2012; supple 2:209–17.
14.
go back to reference Matsuo S, Kawamura T, Joh K, Utsunomiya Y, Okonogi H, Miyazaki Y, et al. Clinical guides for immunoglobulin A (IgA) nephropathy in Japan, third version. Jpn J Nephrol. 2011;53:123–35. Matsuo S, Kawamura T, Joh K, Utsunomiya Y, Okonogi H, Miyazaki Y, et al. Clinical guides for immunoglobulin A (IgA) nephropathy in Japan, third version. Jpn J Nephrol. 2011;53:123–35.
15.
go back to reference Kawamura T, Joh K, Okonogi H. Koike K, Utsunomiya Y, Miyazaki Y et al. A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end stage renal disease. J Nephrol. 2013;26:350–7. Kawamura T, Joh K, Okonogi H. Koike K, Utsunomiya Y, Miyazaki Y et al. A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end stage renal disease. J Nephrol. 2013;26:350–7.
16.
go back to reference Szeto CC, Lai FM, To KF, Wong TY, Chow KM, Choi PC, et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001;100:434–7.CrossRef Szeto CC, Lai FM, To KF, Wong TY, Chow KM, Choi PC, et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001;100:434–7.CrossRef
17.
go back to reference Shen P, He L, Li Y, Wang Y, Chan M. Natural history and prognostic factors of IgA nephropathy presented with isolated microscopic hematuria in Chinese patients. Nephron Clin Pract. 2007;106:c157–61.PubMedCrossRef Shen P, He L, Li Y, Wang Y, Chan M. Natural history and prognostic factors of IgA nephropathy presented with isolated microscopic hematuria in Chinese patients. Nephron Clin Pract. 2007;106:c157–61.PubMedCrossRef
18.
go back to reference Kim BS, Kim YK, Shin YS, Kim YO, Song HC, Kim YS, et al. Natural history and renal pathology in patients with isolated microscopic hematuria. Korean J Int Med. 2009;24:356–61.CrossRef Kim BS, Kim YK, Shin YS, Kim YO, Song HC, Kim YS, et al. Natural history and renal pathology in patients with isolated microscopic hematuria. Korean J Int Med. 2009;24:356–61.CrossRef
19.
go back to reference Manno C, Strippoli GF, D’Altri C, Torres D, Rossini M, Schena FP. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis. 2007;49:763–5.PubMedCrossRef Manno C, Strippoli GF, D’Altri C, Torres D, Rossini M, Schena FP. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis. 2007;49:763–5.PubMedCrossRef
20.
go back to reference Rauta V, Finne P, Fagerudd J, Rosenlof K, Tornroth T, Gronhagen-Riska C. Factors associated with progression of IgA nephropathy are related to renal function—a model for estimating risk of progression in mild disease. Clin Nephrol. 2002;58:85–94.PubMedCrossRef Rauta V, Finne P, Fagerudd J, Rosenlof K, Tornroth T, Gronhagen-Riska C. Factors associated with progression of IgA nephropathy are related to renal function—a model for estimating risk of progression in mild disease. Clin Nephrol. 2002;58:85–94.PubMedCrossRef
Metadata
Title
Comparison between consecutive and intermittent steroid pulse therapy combined with tonsillectomy for clinical remission of IgA nephropathy
Authors
Daigo Kamei
Takahito Moriyama
Takashi Takei
Sachiko Wakai
Kosaku Nitta
Publication date
01-04-2014
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 2/2014
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-013-0822-8

Other articles of this Issue 2/2014

Clinical and Experimental Nephrology 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine